Skip to main content

Table 5 The most targeted diseases stratified by origin of sponsor

From: Map of biomedical research in Cameroon; a documentary review of approved protocols from 1997 to 2012

Diseases Total (%) Local sponsors (%) International Sponsor (%) p-value
Diabetes 101 (7.6) 90 (8.1) 11 (5.1) 0.13
HIV/AIDS 342 (25.8) 306 (27.6) 36 (16.7) <0.001
Malaria 136 (10.3) 99 (8.9) 37 (17.2) <0.001
Tuberculosis 44 (3.3) 39 (3.5) 5 (2.3) 0.37
Reproductive Health 33 (2.5) 29 (2.6) 4 (1.9) 0.55
Cancers 77 (5.8) 53 (4.8) 24 (11.2) <0.001
Neurological/Mental Health 61 (4.6) 49 (4.4) 12 (5.6) 0.44
Cardiovascular Diseases 64 (4.8) 57 (5.1) 7(3.3) 0.26
Metabolic Diseases 37 (2.8) 33 (3.0) 4 (1.9) 0.37
Digestive System 54 (4.1) 51 (4.6) 3 (1.4) 0.03
Tropical/Infectious Diseases 126 (9.5) 107 (9.7) 19 (8.8) 0.68
Eye Diseases 19 (1.4) 15 (1.3) 4 (1.9) 0.49
Respiratory system diseases 38 (2.9) 29 (2.6) 9 (4.2) 0.20
STI/STD 17(1.3) 14(1.3) 3 (1.4) 0.91
Hepatitis 44 3.3) 35(3.20) 9 (4.2) 0.46
Others 130 (9.8) 102 (9.2) 28 (13.0) 0.09
Total 1323 1108 215  
  1. P-value <0.01: strong evidence; <0.05: good evidence